Drug General Information (ID: DDISHZX0C8)
Drug Name			Epirubicin		Drug Info		Asparaginase Erwinia chrysanthemi		Drug Info
Drug Type		Small molecule				Protein/peptide
Therapeutic Class		Antineoplastics				Antineoplastics

Mechanism of Epirubicin-Asparaginase Erwinia chrysanthemi Interaction (Severity Level: Moderate)
Increased risk of hepatotoxicity Click to Show/Hide Mechanism Graph
Drug Name		Epirubicin				Asparaginase Erwinia chrysanthemi
Mechanism		Hepatotoxicity				Hepatotoxicity
Key Mechanism Factor 1
		Factor Name		Hepatotoxicity
		Factor Description		Combination of drugs that can induce hepatotoxicity may increase the risk of liver injury. Symptoms vary depending on the level of exposure and the total extent of liver damage, and may cause few symptoms if the damage is mild, and eventually lead to liver failure in patients with severe damage.
Mechanism Description		Increased risk of hepatotoxicity by the combination of Epirubicin and Asparaginase Erwinia chrysanthemi

Recommended Action
Management		Caution and clinical and laboratory monitoring for signs of liver injury are advisable before, during, or after use of epirubicin with other agents that are potentially hepatotoxic.

References
1	Cerner Multum, Inc. "Australian Product Information.".
2	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
3	Product Information. Ellence (epirubicin) Pharmacia and Upjohn, Kalamazoo, MI.